Scholarlink

Background <p>Patients undergoing cancer treatment often endure significant symptom burden, necessitating timely management to prevent severe complications. The COVID-19 pandemic highlighted the need for real-time remote symptom monitoring, particularly for cancer patients at heightened risk due to immunosuppression from cancer and chemotherapy.</p> Methods <p>This 24-week, single-arm intervention study was conducted from July 2020 to May 2021 at the Stephenson Cancer Center Infusion Clinic in Oklahoma, USA. This study assessed the feasibility, acceptability, and utility of the Symptom Tracker smartphone app. The app prompted 128 patients receiving cytotoxic chemotherapy to report symptoms associated with cancer, cancer treatment, and COVID-19. Reports indicating elevated COVID-19 risk automatically triggered notifications to nursing staff for follow-up and testing. Primary outcomes included daily symptom reporting adherence and patient satisfaction.</p> Results <p>Participants (<i>N</i> = 128) had a mean age of 57.6 years (SD = 13.0), with 77.3% being female. Approximately 10,000 daily symptom reports were completed, representing 46% of all study days. The app facilitated 302 patient-initiated contacts with cancer treatment staff. During the study period, seven participants (5.5%) tested positive for COVID-19 and were successfully triaged. Weekly feedback revealed that 76.8%-89.1% of participants considered the frequency of assessments “about right.”</p> Conclusion <p>The Symptom Tracker app demonstrated feasibility, acceptability, and utility, as evidenced by high symptom reporting adherence, user satisfaction, and effective remote symptom management across a diverse patient population in Oklahoma. Our approach shows promise for supporting oncology care, enhancing real-time monitoring of symptom variability, and ensuring rapid response to critical symptoms.</p> Trial Registration <p>ClinicalTrials.gov Identifier: NCT04397614, Registration date: May 22, 2020.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A mobile health app for real-time symptom monitoring in patients with cancer during COVID-19: feasibility, acceptability, and utility

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月20日

查看全文
  • Ruosi Shao,
  • Jordan M. Neil,
  • Meng Chen,
  • Bethany Hannafon,
  • Ryan Nipp,
  • Audrey Montgomery,
  • Summer G. Frank-Pearce,
  • Katherine Moxley,
  • Debra L. Richardson,
  • Jacey Elliott,
  • Lizbeth Benson,
  • Amy Gin Gossett,
  • Michael S. Businelle

摘要

Background

Patients undergoing cancer treatment often endure significant symptom burden, necessitating timely management to prevent severe complications. The COVID-19 pandemic highlighted the need for real-time remote symptom monitoring, particularly for cancer patients at heightened risk due to immunosuppression from cancer and chemotherapy.

Methods

This 24-week, single-arm intervention study was conducted from July 2020 to May 2021 at the Stephenson Cancer Center Infusion Clinic in Oklahoma, USA. This study assessed the feasibility, acceptability, and utility of the Symptom Tracker smartphone app. The app prompted 128 patients receiving cytotoxic chemotherapy to report symptoms associated with cancer, cancer treatment, and COVID-19. Reports indicating elevated COVID-19 risk automatically triggered notifications to nursing staff for follow-up and testing. Primary outcomes included daily symptom reporting adherence and patient satisfaction.

Results

Participants (N = 128) had a mean age of 57.6 years (SD = 13.0), with 77.3% being female. Approximately 10,000 daily symptom reports were completed, representing 46% of all study days. The app facilitated 302 patient-initiated contacts with cancer treatment staff. During the study period, seven participants (5.5%) tested positive for COVID-19 and were successfully triaged. Weekly feedback revealed that 76.8%-89.1% of participants considered the frequency of assessments “about right.”

Conclusion

The Symptom Tracker app demonstrated feasibility, acceptability, and utility, as evidenced by high symptom reporting adherence, user satisfaction, and effective remote symptom management across a diverse patient population in Oklahoma. Our approach shows promise for supporting oncology care, enhancing real-time monitoring of symptom variability, and ensuring rapid response to critical symptoms.

Trial Registration

ClinicalTrials.gov Identifier: NCT04397614, Registration date: May 22, 2020.